

CORRECTION

Open Access



Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

Simron Singh¹, Diego Ferone², Jaume Capdevila³, Jennifer Ang Chan⁴, Wouter W. de Herder⁵, Daniel Halperin⁶, Josh Mailman⁷, Lisa Hellström⁸, Hanna Liedman⁸, Agneta Svedberg⁸ and Fredrik Tiberg^{8*}

Correction: *Trials* 25, 58 (2024)
<https://doi.org/10.1186/s13063-023-07834-8>

Following publication of the original article [1], we have been notified that a correction is needed on page 3, paragraph 2 as shown below:

Incorrect statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of

both octreotide LAR and lanreotide ATG requires medical assistance.”

Correct statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of octreotide LAR requires medical assistance. For patients who receive a stable dose of lanreotide ATG, the product can be administered either by the patient or by a trained person (Reference Somatuline Autogel 60 mg, solution for injection in a prefilled syringe—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk)).”

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1186/s13063-023-07834-8>.

*Correspondence:

Fredrik Tiberg

Fredrik.Tiberg@camurus.com

¹ Sunnybrook Health Sciences Center, Toronto, Canada

² Endocrinology, Department of Internal Medicine & Medical Specialties, University of Genova, Endocrinology Clinic IRCCS Ospedale Policlinico San Martino, Genoa, Italy

³ Vall d'Hebron University Hospital, Barcelona, Spain

⁴ Dana-Farber Cancer Institute, Boston, MA, USA

⁵ Erasmus MC & Erasmus MC Cancer Institute, Rotterdam, The Netherlands

⁶ The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁷ Northern California Carcinet Community, Oakland, CA, USA

⁸ Camurus AB, Lund, Sweden

Published online: 02 May 2024

Reference

1. Singh S, et al. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. *Trials*. 2024;25:58. <https://doi.org/10.1186/s13063-023-07834-8>.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.